Nick Scott1,2, Mark Stoové1,2, Sherrie L Kelly1,2, David P Wilson1, Margaret E Hellard1,2,3. 1. Disease Elimination, Burnet Institute, Melbourne. 2. Department of Epidemiology and Preventive Medicine, Monash University, Clayton. 3. Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Australia.
Abstract
Background: We estimated the human immunodeficiency virus (HIV) incidence reduction in Australia that would correspond to achieving the United Nations Program on HIV and AIDS (UNAIDS) 90-90-90 targets by 2020 and extended targets of 95-95-95 by 2030. This was done in combination with various scale-ups of HIV testing, primary prevention, and preexposure prophylaxis (PrEP) among high-risk men who have sex with men (MSM). These projections were evaluated against the target of achieving a 90% reduction in HIV incidence by 2030 compared with 2010 levels. Methods: A mathematical model. Results: Achieving 90-90-90 by 2020 was estimated to reduce incidence by 10% from 2010 levels. Achieving 95-95-95 by 2030 was estimated to reduce incidence by 17% from 2010 levels, with the first "95" being achievable by testing low- and high-risk MSM 2 and 4 times per year, respectively. This was improved to a 34% reduction by including a 5-year scale-up of PrEP to 30% coverage among high-risk MSM and to 45% by also increasing MSM condom use from 42% to 60%. However, even with 95-95-95, 2 and 4 tests per year for low- and high-risk MSM, 100% high-risk MSM PrEP coverage, and 100% MSM condom use, only an 80% reduction in incidence was possible by 2030. Conclusions: Many countries, particularly those with low HIV prevalence, will struggle to achieve a 90% reduction in HIV incidence by 2030, even if UNAIDS targets are met. Most will require substantially higher levels of prevention coverage and higher testing frequencies to reach this target.
Background: We estimated the human immunodeficiency virus (HIV) incidence reduction in Australia that would correspond to achieving the United Nations Program on HIV and AIDS (UNAIDS) 90-90-90 targets by 2020 and extended targets of 95-95-95 by 2030. This was done in combination with various scale-ups of HIV testing, primary prevention, and preexposure prophylaxis (PrEP) among high-risk men who have sex with men (MSM). These projections were evaluated against the target of achieving a 90% reduction in HIV incidence by 2030 compared with 2010 levels. Methods: A mathematical model. Results: Achieving 90-90-90 by 2020 was estimated to reduce incidence by 10% from 2010 levels. Achieving 95-95-95 by 2030 was estimated to reduce incidence by 17% from 2010 levels, with the first "95" being achievable by testing low- and high-risk MSM 2 and 4 times per year, respectively. This was improved to a 34% reduction by including a 5-year scale-up of PrEP to 30% coverage among high-risk MSM and to 45% by also increasing MSM condom use from 42% to 60%. However, even with 95-95-95, 2 and 4 tests per year for low- and high-risk MSM, 100% high-risk MSM PrEP coverage, and 100% MSM condom use, only an 80% reduction in incidence was possible by 2030. Conclusions: Many countries, particularly those with low HIV prevalence, will struggle to achieve a 90% reduction in HIV incidence by 2030, even if UNAIDS targets are met. Most will require substantially higher levels of prevention coverage and higher testing frequencies to reach this target.
Authors: Dawn K Smith; Patrick S Sullivan; Betsy Cadwell; Lance A Waller; Azfar Siddiqi; Robertino Mera-Giler; Xiaohong Hu; Karen W Hoover; Norma S Harris; Scott McCallister Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Tafireyi Marukutira; Mark Stoové; Shahin Lockman; Lisa A Mills; Tendani Gaolathe; Refeletswe Lebelonyane; Joseph N Jarvis; Sherrie L Kelly; David P Wilson; Stanley Luchters; Suzanne M Crowe; Margaret Hellard Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396
Authors: R Clive Landis; E Akinola Abayomi; Brendan C Bain; Edward Greene; George Janossy; Patrice Joseph; Deanna Kerrigan; J Philip McCoy; Cesar Nunez; Maurice O'Gorman; Alexander Pastoors; Bharat S Parekh; Kim R Quimby; Thomas C Quinn; Kevin R Robertson; Réjean Thomas; Eric van Gorp; Sten H Vermund; Valerie Wilson Journal: AIDS Res Hum Retroviruses Date: 2018-06-05 Impact factor: 2.205
Authors: N N Abuelezam; A W McCormick; E D Surface; T Fussell; K A Freedberg; M Lipsitch; G R Seage Journal: Epidemiol Infect Date: 2019-01 Impact factor: 2.451
Authors: Ngai Sze Wong; Tsz Ho Kwan; Owen T Y Tsang; Man Po Lee; Wing Cheong Yam; Wilson Lam; Wai Shing Leung; Jacky M C Chan; Kai Man Ho; Shui Shan Lee Journal: Sci Rep Date: 2018-08-03 Impact factor: 4.379
Authors: Denton Callander; Clarissa Moreira; Margaret Hellard; Rebecca Guy; Carol El-Hayek; Jason Asselin; Caroline van Gemert; Lucy Watchirs Smith; Long Nguyen; Wayne Dimech; Douglas Ir Boyle; Basil Donovan; Mark Stoové Journal: JMIR Res Protoc Date: 2018-11-20
Authors: Tafireyi Marukutira; Richard T Gray; Caitlin Douglass; Carol El-Hayek; Clarissa Moreira; Jason Asselin; Basil Donovan; Tobias Vickers; Tim Spelman; Suzanne Crowe; Rebecca Guy; Mark Stoove; Margaret Hellard Journal: PLoS Med Date: 2020-03-10 Impact factor: 11.069
Authors: Adrien Le Guillou; Susan Buchbinder; Hyman Scott; Albert Liu; Diane Havlir; Susan Scheer; Samuel M Jenness Journal: J Acquir Immune Defic Syndr Date: 2021-12-01 Impact factor: 3.771
Authors: Tafireyi Marukutira; Praveena Gunaratnam; Caitlin Douglass; Muhammad S Jamil; Skye McGregor; Rebecca Guy; Richard Thomas Gray; Tim Spelman; Danielle Horyniak; Nasra Higgins; Carolien Giele; Suzanne Mary Crowe; Mark Stoove; Margaret Hellard Journal: Medicine (Baltimore) Date: 2020-02 Impact factor: 1.817